Behavioural and pharmacological effects of cannabidiol (CBD) and the cannabidiol analogue KLS‐13019 in mouse models of pain and reinforcement

Background and Purpose Cannabidiol (CBD) is a non-euphorigenic component of Cannabis sativa that prevents the development paclitaxel-induced mechanical sensitivity in mouse model chemotherapy-induced peripheral neuropathy (CIPN). We recently reported CBD structural analogue KLS-13019 shows efficacy an vitro CIPN. The present study was to characterize behavioural effects compared morphine models CIPN, nociceptive pain reinforcement. Experimental Approach Prevention or reversal were assessed following intraperitoneal oral administration CBD, morphine. Antinociceptive activity using acetic acid-induced stretching hot plate assay, anti-reinforcing on palatable food self-administration binding human opioid receptors also determined. Key Results Like prevented associated with paclitaxel administration. In contrast effective at reversing established sensitivity. significantly attenuated produced modest assay. devoid μ-, δ- κ-opioid receptors. Lastly, KLS-13019, but not reinforcing Conclusions Implications like while uniquely Because binds fewer biological targets, this will help identifying molecular mechanisms shared by these two compounds those unique KLS-13019. may possess ability attenuate reinforced behaviour, effect observed CBD.